Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AFQ065 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| AFQ065 | DRUG | - |
Inclusion Criteria: * Healthy, male \& female subjects at least 18 years and ≤60 years of age * In good health * Female subjects must be surgically sterilized or postmenopausal. * Current smokers not intending to quit * Smoke on average 15 cigarettes or more and less than 60 cigarettes a day for th...
AFQ065 is an investigational small molecule being studied for smoking abstinence, a psychiatry indication. It is being developed by Novartis AG (NVS). The drug is currently in Phase 1 clinical development and is not approved by the FDA.
AFQ065 is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker NVS. The drug is an investigational small molecule in Phase 1 clinical development for smoking abstinence.
AFQ065 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 1 trial has been completed, and the drug is not currently in any active clinical trials.
AFQ065 has one completed Phase 1 clinical trial, identified as NCT00414752, titled "Effects of AFQ056 and Nicotine in Reducing Cigarette Smoking." The trial enrolled 36 participants in Germany and was a randomized, double-blind, uncontrolled study involving healthy volunteers.
The completed clinical trial for AFQ065, NCT00414752, is titled "Effects of AFQ056 and Nicotine in Reducing Cigarette Smoking," which suggests AFQ065 may be related to or the same as AFQ056. However, the drug is listed as AFQ065 in the trial record.